Revised SPC: Zolgensma (onasemnogene abeparvovec) 2 x 10Exp13 vector genomes/mL solution for infusion
A warning for thrombotic microangiopathy has been added. Cases of thrombotic microangiopathy (TMA) have been reported to occur approximately one week after onasemnogene abeparvovec infusion
Source:
electronic Medicines compendium